Increased intestinal permeability and tight junction disruption by altered expression and localization of occludin in a murine graft versus host disease model by Rainer Noth et al.
RESEARCH ARTICLE Open Access
Increased intestinal permeability and tight
junction disruption by altered expression and
localization of occludin in a murine graft versus
host disease model
Rainer Noth1, Julia Lange-Grumfeld1, Eckhard Stüber1, Marie-Luise Kruse1, Mark Ellrichmann1, Robert Häsler2,
Jochen Hampe1, Burkhard Bewig1, Philip Rosenstiel2, Stefan Schreiber1,2 and Alexander Arlt1*
Abstract
Background: Hematopoietic stem cell transplantation is increasingly performed for hematologic diseases. As a
major side effect, acute graft versus host disease (GvHD) with serious gastrointestinal symptoms including diarrhea,
gastrointestinal bleeding and high mortality can be observed. Because surveillance and biopsies of human
gastrointestinal GvHD are difficult to perform, rare information of the alterations of the gastrointestinal barrier exists
resulting in a need for systematic animal models.
Methods: To investigate the effects of GvHD on the intestinal barrier of the small intestine we utilized an
established acute semi allogenic GvHD in C57BL/6 and B6D2F1 mice.
Results: By assessing the differential uptake of lactulose and mannitol in the jejunum, we observed an increased
paracellular permeability as a likely mechanism for disturbed intestinal barrier function. Electron microscopy,
immunohistochemistry and PCR analysis indicated profound changes of the tight-junction complex, characterized
by downregulation of the tight junction protein occludin without any changes in ZO-1. Furthermore TNF-a
expression was significantly upregulated.
Conclusions: This analysis in a murine model of GvHD of the small intestine demonstrates serious impairment of
intestinal barrier function in the jejunum, with an increased permeability and morphological changes through
downregulation and localization shift of the tight junction protein occludin.
Background
Hematopoietic stem cell transplantation is an estab-
lished treatment modality for a wide range of hematolo-
gic malignancies [1]. After bone marrow transplantation,
T cells present in the graft, either as contaminants or
intentionally introduced into the host, can attack the
host tissues of the transplant recipient by recognition of
host tissues as foreign antigens. The T cells produce an
excess of cytokines like TNF-a and interferon-gamma
(IFNg) which in turn lead to a pro-inflammatory envir-
onment. This graft-versus-host-disease (GvHD) affects
up to 70% of patients who undergo stem cell transplan-
tation and is clinically divided into acute and chronic
forms which also involve different immune cell subsets
and cytokine profiles [1-4].
The acute form of the disease is mostly observed
within the first 100 days post-transplantion, and is a
major challenge to transplants owing to associated mor-
bidity and mortality [1,5]. Classically, acute GvHD is
characterized by selective damage to liver, skin and the
gastrointestinal (GI) tract. The manifestation in the GI
tract (GI GvHD) can result in severe diarrhea, abdom-
inal pain, nausea, and vomiting. The gastrointestinal
manifestation of the disease is typically diagnosed via
intestinal biopsy. However, risk of endoscopy is higher
in these ill patients and frequently thrombocytopenia
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complicates mucosal biopsies [6]. Histological findings
that support the diagnosis are nonspecific and have lim-
ited sensitivity and specificity [2]. In addition, specific
options for treatment of GvHD of the intestine [3,6] are
currently lacking. The problem in the diagnosis and
treatment of GI GvHD are due to the still limited
understanding of the pathophysiology of the disease.
However it is well established that disruption of the
mucosal barrier leads to the GI-symptoms and the
increase in morbidity and mortality [2,3].
Murine acute GVHD has long been investigated for
two reasons: as an animal model for the immune patho-
mechanisms of human GVHD after allogenic bone mar-
row transplantation. Furthermore, due to its
characteristic changes in the intestinal histology consist-
ing of lymphocytic infiltrates, crypt hyperplasia, and vil-
lous atrophy, it serves as a model for immunologically
mediated atrophic-hyperregenerative diseases of the
intestine (29, 30). By improving the understanding of
the pathophysiology of GI GVHD more focused and
effective diagnostic and therapeutic options could be
implemented leading to reduced morbidity and
mortality.
The aim of this study was to evaluate effects of a GI
GvHD in a mouse model regarding the functions of the
gastrointestinal barrier by analysing the intestinal per-
meability and the composition of the tight junctions.
Our analysis showed a seriously impaired intestinal bar-
rier function with an increased permeability associated
with an upregulation of TNF-a expression and downre-




C57BL/6, DBA/2 mice and the F1 intercross of these
two mouse strains (B6D2F1) were raised and kept under
standard conditions in the animal facility of the Univer-
sity Hospital of Kiel, Germany. Animal care and experi-
ments were approved by the local commitee for animal
use (Az 28-5/96).
To induce semi-allogenic graft-versus host disease, a
slightly modified procedure as described by [7] was per-
formed. To prepare donor lymphocytes, spleen and
mesenterial lymph nodes of C57BL/6 mice were
removed and pressed through a cell filter (40 μm pore
size). Red blood cells were subsequently lysed by a
hypotonic lysing buffer (ACK-buffer, Boehringer Ingel-
heim, Germany) The resulting lymphocytes (80 × 106
cells/animal) were transferred to 8-14-week-old irra-
diated (7,5 Gy) B6D2F1 mice of the same sex by intra-
peritoneal injection. Six days after the induction of
semi-allogenic GvHD, recipient animals were killed. The
small bowel (jejunum) was removed and frozen in liquid
nitrogen or fixed in 10% phosphate buffered (pH 7.4)
formalin for further analysis. Irradiated B6D2F1 mice,
which were transferred with the same amount of syn-
genic (B6D2F1) cells served as controls.
Measurement of intestinal permeability
Intestinal permeability was determined using two non-
metabolized sugars. Threehundred mililiters lactulose
and 200 mg mannitol were dissolved in 20 ml distilled
water. After a fasting period of 12 hours, GvHD-mice
and control animals received 1 ml of the lactulose/man-
nitol solution by orogastral tube. One hour after feeding,
blood was taken from the sinus cavernosus under anaes-
thesia with ether. Serum concentrations of lactulose and
mannitol were determined using melibiose as internal
standard as described below.
Measurement of lactulose and mannitol serum
concentrations
Mannitol and the disaccharide lactulose, (4-0-ß-D-galac-
topyranosyl-D-fructofuranose) for oral administration
were obtained from Fluka (Seelze, Germany) and Cal-
biochem (San Diego, Ca, USA) while melibiose for inter-
nal standards was supplied from Sigma (Deisenhofen,
Germany). The high-performance-liquid-chromatogra-
phy (HPLC) equipment was from Merck (Darmstadt,
Germany) and comprised an eluent degas module, a
micro injection valve fitted with a 25 μl loop and a gra-
dient pump. The pulsed amperometric detector (PAD)
with a gold electrode and a silver/silver chloride refer-
ence electrode, a Carbopac® PA 100 anion exchange
column and a guard column filled with the same mate-
rial was from Dionex (Idstein, Germany). Data were pro-
cessed using a Merck integrator D7500. Deionised water
with high resistance (18 M Ώ/per XYZ) for dilution of
samples and eluent was from Merck.
Eluent preparation
High-performance-liquid-chromatography water was
degassed by sparkling with helium for 15 minutes. Fifty
percent sodium hydroxide solution was added and
gently stirred for 5 minutes to achieve the required con-
centration of 90 mM NaOH.
Sample preparation (serum)
Serum was separated from whole-blood samples by a 10
minute centrifugation at 3000 rpm and was stored after-
wards at -20°C for up to two months until analysis. An
aliquot of 0.5 ml serum was deproteinised by precipita-
tion with 5% 5-sulfosalicylic acid and 200 μl of the
internal standard (melibiose 0.1 mg/l) was added. After
a 15 minutes incubation period (4°C), the samples were
centrifuged at 9000 rpm for 5 minutes and the superna-
tants were removed and diluted (1:100) with 90 mmol/l
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NaOH. Twenty five microliters of this supernatant were
then applied onto the anion exchange column.
Analyses of carbohydrates with HPLC and pulsed
amperometric detection (PAD)
The samples were eluted with the 90 mmol NaOH elu-
ent at a flow rate of 1 ml/min at 25°C. Analytes were
separated through the Carbopac® 100 anion exchange
column and detected with a pulsed amperometric detec-
tor (PAD) using a gold working electrode and a silver/
silver chloride reference electrode. A repeating sequence
of three different potentials was used. Carbohydrates
were detected by measuring the electrical current gener-
ated by their oxidation at the surface of a gold electrode
(E1: 0.05 V, T1: 0.4 sec.). The second potential oxidized
the gold electrode to clean the surface (E2: 0.75 V, T2
0.2 sec.). The third potential reduced the gold oxide on
the electrode surface back to gold, thus permitting a
new detection during the next cycle (E3: -0.15 V, T3:
0.4 sec). Sensitivity on the PAD was set to 100 nC. Cal-
culation of sugar concentration was performed by inte-
grator analysis of the area of the melibiose reference
peak and the area of the mannitol and lactulose peaks.
Electron microscopy
The jejunum specimens were fixed for at least four
hours in Karnovsky solution (2.5% glutaraldehyde and
2% paraformaldehyde in 0.1 M sodium-cacodylate-buf-
fer, pH 7.0). The fixed samples were washed three times
for ten minutes with a 0.1 M sodium-cacodylate-buffer
(pH 7.0) followed by a second fixation in 1% cacodylate-
buffered osmiumtetroxide solution (Roth, Karlsruhe,
Germany). Dehydration with ethanol was followed by
imbedding with Araldit (Serva, Germany). For contrast-
ing, uranylacetate treatment of the ultrathin sections
was performed subsequently. A Zeiss electron micro-
scope (EM 902, Zeiss, Jena, Germany) was used for
imaging.
Immune fluorescence microscopy
Snap-frozen jejunum samples were cut into 1 μm sec-
tions at -24°C. These sections were dried, fixed with
acetone and rehydrated in phosphate-buffered saline
(Dulbecco’s PBS (1×), PAA Laboratories GmbH, Aus-
tria). To suppress unspecific background, fluorescence
blocking reagent Vectastain EliteABC-Kit (Rabbit IgG,
Vector Laboratories, Servion, Switzerland) was applied
followed by incubation with the primary antibody rab-
bit-anti-occludin and rabbit-anti-ZO-1 (Zymed Labora-
tories, USA). After washing with PBS, incubation with
the fluorescent secondary antibody Alexa Fluor® 488
anti-rabbit (Invitrogen™, Molecular Probes™, Oregon,
USA) followed. After washing with PBS, Phalloidin
(Sigma) was applied as a cytoskeleton dye. For staining
of nucleic acids, DAPI was used (Sigma, USA). Imaging
was performed with the fluorescence microscope Axion
imager Z.1 (Carl Zeiss MicroImaging GmbH, Jena, Ger-
many) and analysed using theAxion Vision (Zeiss)
software.
Expression analysis
RNA isolation and cDNA synthesis
Total RNA was extracted from frozen biopsies using
silica gel-based spin columns (RNeasy Kit; QIAGEN,
Hilden, Germany). Genomic DNA was digested by treat-
ment with deoxyribonuclease I (QIAGEN). Reverse tran-
scription of 2 mg RNA was performed using 0.5 μg
oligo (dT)15-primers (You prime First strand cDNA
synthesis kit; Amersham Biosciences, Freiburg, Ger-
many) according to the manufacturer’s instructions.
Primers
Specific intron-spanning primers for TNF-a, occludin
and ZO-1 were designed using the Primer3 software [8]
Oligonucleotides were obtained from Sigma ARK
(Darmstadt, Germany). The oligonucleotide sequences
are depicted as followed: 5’-TGA AGG TCG GTG TGA
ACG GAT -3 (G3PDH fwd, GenBank Accession #
NM_002046) and 5’-CAT GTA GGC CAT GAG GTC
CAC -3’ (G3PDH rev’); 5’-AGA CTA CAC GAC AGG
TGG GG -3’ (Occludin fwd, NM_008756) and 5’-CTG
CAG ACC TGC ATC AAA AT -3’ (Occlucin rev); 5’-
GCA GAC TTC TGG AGG TTT CG -3’ (ZO-1 fwd,
NM_009386) and 5’-CTT GCC AAC TTT TCT CTG
GC -3’ (ZO-1 rev); 5’-TCT ACT GAA CTT CGG GGT
GA -3’(TNF-a fwd, NM_013693) and 5’-CAC TTG
GTG GTT TGC TAC GA -3’ (TNF-a rev)
Polymerase chain reaction (PCR)
PCR was performed with Gene Amp® PCR system 9700
(Applied Biosystems, USA) using two microliters of
cDNA dissolved in H2O, primer F/R (1.0 μl), GoTaq
DNA-Polymerase (0.1 μl), dNTP mix (0.2 μl), 5 × Green
GoTaq Reaction Buffer (4.0 μl) and autoclaved H2O
(12.7 μl). Samples were loaded into capillary tubes and
incubated in the PCR-machine with initial denaturation
at 94°C for 5 min, followed by 32-40 cycles (G3PDH 32,
occludin/ZO-1 35, TNF-a 40), each cycle consisting of
94°C for 30 sec. for denaturation, primer specific anneal-
ing temperature for 30 sec., and 72°C for 30 sec to one
minute for elongation.
Data analysis
Differences between experimental groups were deter-
mined by quantification of the fold change, which was
based on the ratio of the medians of the two compared
groups. Significance was determined by using the
Mann-Whitney U-test, p-values were corrected for mul-
tiple testing (here: 8 parameters) using the Benjamini-
Hochberg correction.
Noth et al. BMC Gastroenterology 2011, 11:109
http://www.biomedcentral.com/1471-230X/11/109
Page 3 of 9
Results
Increased paracellular intestinal permeability
Six days after induction of the semi allogenic GvHD,
intestinal permeability was assessed by differential
uptake of lactulose and mannitol in GvHD animals (n =
20) and controls (n = 18). For demonstration of the
effects of the irradiation alone differential uptake of lac-
tulose and mannitol of B6D2F1 mice was measured
(Figure 1). At this time point the GvHD animals showed
a slightly lower weight and are swelling of the intestine
in cross anatomy (data not shown).
The measurement of mannitol and lactulose by HPLC
analysis showed higher levels of both sugars in compari-
son to the internal standard melibiose indicating
impaired gastrointestinal permeability (Figure 1A). Man-
nitol levels, an indicator for transcellular permeability,
were 443.33 mg/ml in the GvHD animals and 192.44
mg/ml in control animals. The increase in lactulose
levels to 277.35 mg/ml in GvHD animals in comparison
to 81.18 mg/ml in control animals indicated a higher
paracellular permeability in the GvHD group (Figure
1A). By comparing the lactulose to mannitol levels (lac-
tulose/mannitol 0.64 in GvHD vs. 0.43 in control ani-
mals, p < 0.05), we were able to show that the
disturbance of the paracellular permeability is statisti-
cally more pronounced (Figure 1B). Statistical testing by
a Man-Whitney U test showed that all observed effects
on the gastrointestinal permeability were statistical
highly significant (Figure 1A and 1B, p < 0.05).
GvHD is characterized by alterations of the morphology
of the tight junctions
Since permeability testing indicated that GvHD of the small
intestine is characterized by an impaired control of the
paracellular permeability we next performed morphological
analysis of the tight junctions by electron microscopy (Fig-
ure 2). In comparison to the control animals (Figure 2A),
GvHD led to discontinuous tight-junction strand with
widening of the paracellular spaces (Figure 2B).
GvHD is associated with upregulation of the
proinflammatory cytokine TNF-a
Since TNF-a have been shown to be a critical compo-
nent of the course of GvHD in general [9] and for the
increased paracellular permeability in DSS induced coli-
tis [10], we next analysed expression of this proinflam-
matory cytokine in specimen of the jejunum by PCR. As
shown in Figure 3, GvHD is associated with a strong
increase of TNF-a expression at mRNA level in com-
parison to the expression observed in the jejunum of
the control animals.
Downregulation of occludin but not ZO-1 expression in
GvHD
The molecular composition of the tight junction by
transmembrane and cytoplasmatic proteins is highly
complex. Due to their reported involvement in disrup-
tion of intestinal barrier function in other disease mod-
els, we focused our analysis on the transmembrane
protein occludin [11] and the intracellular protein ZO-1
[12]. We showed by rtPCR, that expression levels of
occludin were significantly reduced in the course of
GvHD (Figure 4A). In contrast, no changes in ZO-1
expression were observed (Figure 4B).
Changes in intracellular localization of occludin in GvHD
Besides alterations of expression levels of tight-junction
proteins, changes of their intracellular localisation can
Figure 1 Gastrointestinal permeability. Intestinal permeability
was determined using lactulose and mannitol. After a fasting period
of 12 hours GvHD-mice (n = 20), control animals (n = 18) and non
irradiated B6D2F1 mice (n = 8) received 1 ml of the lactulose/
mannitol solution by orogastral tube. One hour after feeding serum
concentrations of lactulose (representative for paracellular
permeability) and mannitol (representative for transcellular
permeability) were determined using melibiose as internal standard
as described. A) mean and SD of mannitol and lactulose serum
concentrations normalized to melbiose. * indicates p-values < 0.05
and ** p-values < 0.01. B) Lactulose/mannitol quotient. * indicates
p-value < 0.05.
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also affect barrier function, as shown recently [11].
Therefore, indirect immunofluorescence staining for
occludin and ZO-1 was performed. Figure 5 shows
fluorescence microscopy of control animals (left panel)
versus GvHD animals (right panel). Occludin staining
was found along the lateral cell walls with enhanced sig-
nals at the apical site under control conditions (Figure 5
top left). Tangential sectioning of epithelial cells showed
a polygonal pattern reminiscent of mesh wire. In con-
trast, analysis of GvHD sections revealed a fuzzy appear-
ance of immune reactivity throughout the cell, leaving
only the nucleus free of staining indicative of re-localisa-
tion from the plasma membrane (Figure 5, top right).
Analysis of ZO-1 distribution showed concentrated
staining at the apical aspect of the plasma membrane in
control slices (Figure 5, middle left) This pattern
appeared only slightly impaired in GvHD animals (Fig-
ure 5, middle, right) Since a recent report indicated
TNF-a induced effects on the interaction of occluding
and ZO-1 with components of the actin cytoskeleton
Figure 2 Electron microscopy of tight junctions of the small
intestine. Morphological analysis of tight junctions of the small
intestine of control animals A) and GvHD animals 2B) by electron
microscopy. Small black arrow = Tight junction, white triangle =
adherens junction, black triangle = desmosome. Representative
results of independent examinations of 10 animals each group.
Figure 3 TNF-a expression in the jejunum. Expression of the
proinflammatory cytokine TNF-a in the specimen of the jejunum of
GvHD-mice (n = 20) and control animals (n = 18) was analysed by
PCR. Mean and SD of TNF-a expression normalized to the
housekeeping gene GAPDH are shown. * indicates p-values < 0.05.
Figure 4 Occludin and ZO-1 expression in the jejunum.
Expression of the tight junction proteins occludin (A)) and ZO-1 (B))
in the specimen of the jejunum of GvHD-mice (n = 20) and control
animals (n = 18) were analysed by PCR. Mean and SD of occludin
(A)) and ZO-1 (B)) expression normalized to the housekeeping gene
GAPDH are shown. * indicates p-values < 0.05.
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[13], the expression of F-actin was analyzed next. Actin
is a major constituent of the terminal web at the apical
plasma membrane. Underlying the brush border of the
epithelium, actin staining apears as a tight line at the
apical aspect of the cells, showing the typical mesh wire-
like pattern in tangential sections of the epithelial cell
layer in control animals (Figure 5, bottom left). In
GvDH animals (Figure 5, bottom right) actin staining in
epithelial cells appeared disrupted and extended, no
longer confined to the terminal web, but mostly diffuse,
or randomly accumulated into denser patches of
staining.
Discussion
Acute graft versus host disease (GvHD) is a severe com-
plication after hematopoietic stem cell transplantation.
Figure 5 Intracellular localization of occludin, ZO-1 and F-actin in the jejunum. Localization of the tight junction proteins occludin (top),
ZO-1 (middle) and the actin skeleton protein F-actin (bottom) in jejunum of GvHD-mice (n = 26) and control animals (n = 16) were analysed by
immunfluorescence microscopy. Representative results of independent examinations of 10 animals each group. Red arrows highlight alterations
in the occludin and F-actin localization.
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The impaired integrity of the gastrointestinal tract dur-
ing GvHD (GI-GvHD) seems to play an important role
in the amplification of the systemic disease.
In this study, we show for the first time that GI-GvHD
leads to tight junction impairment with subsequently
increased paracellular permeability. In the murine T-cell
mediated acute GI-GvHD model used in this study, the
transmembrane tight junction protein occludin is down-
regulated and its mesh wire-like appearance within the
apical tight-junction complex is lost due to cytoplasmic
re-localization. Furthermore, we observed an increased
expression of TNF-a which might in turn lead to the
observed changes in occludin expression and/or
localization.
Our findings are in line with other studies on T-cell
mediated small bowel diseases which found increased
paracellular permeability [14-19]. Tight-junction pro-
teins are essential for the integrity of the intestinal bar-
rier by building the most apical structure and regulating
paracellular permeability and polarity of the cell. The
tight-junction composition is a highly dynamic process
and different tight-junction components can be divided
into the transmembrane proteins (occludin, the claudin
protein family, junctional adhesion molecules, coxsackie
adenovirus receptor and tight-junction associated marvel
proteins) and cytoplasmatic proteins (ZO-1 and cingu-
lin). Furthermore, F-actin and myosin, as part of the
cytoskeleton [20,21], are involved in the composition of
the tight junctions. Interactions between tight-junction
proteins, kinase activation and cytokine release influence
the regulation of two transepithelial molecular pathways:
a high-capacity, charge selective pore pathway for small
uncharged molecules influenced primarily by claudin
expression and a low-capacity leak pathway for larger
ions regardless of charge regulated by the cytoskeleton
involving ZO-1 and occludin. We observed a downregu-
lation of occludin and a shift from the membrane to the
cytoplasm without any significant changes in ZO-1
expression. Hypothetically, this could be an important
cause of the observed increased permeability. Occludin
is known to interact with other tight-junction proteins
like ZO-1 and F-actin, mediating signal transduction,
tissue growth and differentiation as well as cytoskeleton
mediated leak pathway regulation [22]. Furthermore, the
function and the localisation seem to differ depending
on posttranslational phosphorylation by enzymes [20].
Fluorescence recovery after photobleaching analyses
showed that occludin is very mobile at the tight-junction
undergoing constant remodelling [23]. In line with our
observations, recent data in colitis associated impaired
barrier function indicated that alterations in the expres-
sion level and localization of occludin are pivotal for
increased paracellular permeability. Interestingly, the
promoter of the occludin gene harbours a TNF-a
response element, negatively regulating the transcription
of occludin [24]. Referring to the pivotal role of TNF-a
in the regulation of gastrointestinal barrier function and
permeability [10,13,16,25-28] and the fact that we
observed a strong upregulation of TNF-a expression, it
is tempting to speculate, that occludin is a central
downstream target of TNF-a in GI-GvHD. It is well
known, that IFN-g production by the donor T cells,
endotoxins and LPS as a component of the normal gut
flora who penetrate the impaired intestinal barrier can
lead to an excessive TNF-a production by monocytes
and macrophages [4,29-31]. This increased TNF-a
expression is associated with the severity of intestinal
GvHD [32] and an elegant recent work showed the
pivotal role of TNF tight junction remodeling and bar-
rier maintenance [13]. Thus, increased TNF-a may
impair the barrier function through disturbance of the
tight junction which in turn results in increased paracel-
lular permeability, enforced translocation of antigens
from the gut into the circulation and an uncontrolled
systemic inflammatory response.
In contrast to colitis model systems in mice [33-35],
we did not observe alterations in the cytoplasmatic tight
junction protein ZO-1. The alterations in the tight junc-
tion complex and its components seem to be dependent
of the disease as indicated by data showing alterations
in only the claudin family in other model systems
[36,37].
By immune fluorescence microscopy, we were able to
show that f-actin was released from the tight organisa-
tion of the terminal web beneath the apical plasma
membrane and showed a mostly diffuse, spreaded
appearance with some more densely packed areas in
irregular patterns in GvDH. This could be due to a con-
traction of the cytoskeleton with tension on the tight-
junction followed by an augmented paracellular channel
as described by other studies [17] or part of the
response of intestinal epithelia to TNF-a induced shed-
ding [13] as reported recently.
Conclusions
In conclusion, the present study demonstrates that the
induction of T-cell mediated acute murine GI-GvHD
leads to an enhanced intestinal permeability character-
ized by high expression of TNF-a leading to a downre-
gulation and localization shift of the tight junction
protein occludin, whereas ZO-1 protein expression and
localisation within the tight junction remains
unchanged. These observations are associated with mor-
phologic changes of the tight-junctions. Further investi-
gations are needed for a better understanding of the
pathophysiological regulation of tight-junctions within
the intestinal T-cell mediated acute GI-GvHD following
bone marrow transplantation to find opportunities to
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influence the barrier defect and therefore these gastroin-
testinal complications.
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